Orgenesis Inc. (ORGS) |
|
1.42 0 (0%)
|
03-24 16:00 |
|
Open: |
1.42 |
Pre. Close: |
1.42 |
|
High:
|
1.4451 |
Low:
|
1.36 |
|
Volume:
|
41,780 |
Market Cap:
|
39(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:28:36 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 2.14 One year: 2.62 |
| Support: |
Support1: 1.15 Support2: 0.96 |
| Resistance: |
Resistance1: 1.83 Resistance2: 2.25 |
| Pivot: |
1.36 |
| Moving Average: |
MA(5): 1.39 MA(20): 1.38
MA(100): 1.9  MA(250): 2.08 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 56.9 %D(3): 56.3 |
| RSI: |
RSI(14): 43.7 |
| 52-week: |
High: 4.03 Low: 1.12 |
| Average Vol(K): |
3-Month: 74 (K) 10-Days: 96 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ORGS ] has closed below upper band by 31.9%. Bollinger Bands are 51% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.45 - 1.46 |
1.46 - 1.46 |
|
Low:
|
1.34 - 1.35 |
1.35 - 1.36 |
|
Close:
|
1.41 - 1.42 |
1.42 - 1.43 |
|
Company Description |
|
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland. |
Headline News |
Tue, 21 Mar 2023
Is Orgenesis Inc (ORGS) Stock a Attractive Value? - InvestorsObserver
Tue, 21 Mar 2023
Orgenesis Inc : Losses of 16 cents announced for fourth ... - Kalkine Media
Tue, 21 Mar 2023
Orgenesis Reports 98% Year-Over-Year Increase in Revenue to $13.6 Million for the Fourth Quarter of 2022 - Yahoo Finance
Tue, 21 Mar 2023
North American Morning Briefing : Stock Futures -2- - Marketscreener.com
Sat, 18 Mar 2023
Orgenesis Schedules Fourth Qua - GuruFocus.com
Thu, 16 Mar 2023
Orgenesis Signs MOU with University of California, Davis to Develop a Collaboration Agreement to Deploy Cell and Gene Therapy Mobile Processing Units and Labs Across California - Marketscreener.com
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Outperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
26 (M) |
| Shares Float |
22 (M) |
|
% Held by Insiders
|
20.2 (%) |
|
% Held by Institutions
|
14.8 (%) |
|
Shares Short
|
225 (K) |
|
Shares Short P.Month
|
209 (K) |
Stock Financials |
|
EPS
|
0.29 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
2.18 |
|
Profit Margin (%)
|
-54 |
|
Operating Margin (%)
|
-50.8 |
|
Return on Assets (ttm)
|
-13.7 |
|
Return on Equity (ttm)
|
-43.3 |
|
Qtrly Rev. Growth
|
-8 |
|
Gross Profit (p.s.)
|
1.38 |
|
Sales Per Share
|
1.14 |
|
EBITDA (p.s.)
|
-0.54 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-17 (M) |
|
Levered Free Cash Flow
|
-1 (M) |
Stock Valuations |
|
PE Ratio
|
4.82 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.65 |
|
Price to Sales
|
1.23 |
|
Price to Cash Flow
|
-2.19 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2017-11-15 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
